Medical Research: Exploiting bacterial minicells for vaccination
Nature Communications
2013년3월13일
A new strategy for the design of potentially safer vaccines is reported in Nature Communications this week. Vaccines based on bacterial minicells may eliminate risks associated with those containing attenuated bacteria, which may still cause disease in children or patients with a weak immune system.
Efficient vaccines deliver antigens, substances that cause an immune response, into immune cells via a bacterial protein injection system known as the type III secretion system (T3SS). However, the T3SS requires energy and is hence only active in live bacteria. Bacterial minicells are the result of aberrant bacterial cell divisions. Although they contain no DNA and cannot replicate, bacterial minicells do contain proteins that sustain some cellular functions. Jorge Galan and collaborators genetically modified minicells of Salmonella Typhimurium so that they contain a functional T3SS. The team went on to show that these minicells could be used to deliver antigens to immune cells via the T3SS and to elicit an immune response in mice.
doi: 10.1038/ncomms2594
리서치 하이라이트
-
6월24일
Sport science: New wearable sensor to measure neck strain may detect potential concussionScientific Reports
-
6월23일
Scientific community: Women credited less than men in scientific paper authorshipNature
-
6월17일
Health technology: New cost-effective smartphone test for middle ear functionCommunications Medicine
-
6월16일
An exercise-inducible molecule that suppresses appetiteNature
-
6월16일
Cancer: Signatures of structural genomic variation in cancerNature
-
6월10일
Animals: Genetic clues to how dogs became man’s best friendsScientific Reports